Advisory Committee on the Medical Uses of Isotopes: Meeting Notice, 50077-50078 [2019-20612]

Download as PDF Federal Register / Vol. 84, No. 185 / Tuesday, September 24, 2019 / Notices U.S.C. 2272(a)), and such supply or production is related to the article or service that was the basis for such certification (as defined in subsection 222(c)(3) and (4) of the Act (19 U.S.C. 2272(c)(3) and (4)); AND (3) either— (A) the workers’ firm is a supplier and the component parts it supplied to the firm described in paragraph (2) accounted for at least 20 percent of the production or sales of the workers’ firm; OR (B) a loss of business by the workers’ firm with the firm described in paragraph (2) contributed importantly to the workers’ separation or threat of separation determined under paragraph (1). Section 222(e)—Firms Identified by the International Trade Commission khammond on DSKJM1Z7X2PROD with NOTICES In order for an affirmative determination to be made for adversely affected workers in firms identified by the International Trade Commission and a certification issued regarding eligibility to apply for TAA, the group eligibility requirements of Section 222(e) of the Act (19 U.S.C. 2272(e))must be met, by following criteria (1), (2), and (3) as follows: (1) the workers’ firm is publicly identified by name by the International Trade Commission as a member of a domestic industry in an investigation resulting in— (A) an affirmative determination of serious injury or threat thereof under section 202(b)(1) of the Act (19 U.S.C. 2252(b)(1)); OR (B) an affirmative determination of market disruption or threat thereof under section 421(b)(1)of the Act (19 U.S.C. 2436(b)(1)); OR (C) an affirmative final determination of material injury or threat thereof under section 705(b)(1)(A) or 735(b)(1)(A) of the Tariff Act of 1930 (19 U.S.C. 1671d(b)(1)(A) and 1673d(b)(1)(A)); AND (2) the petition is filed during the 1year period beginning on the date on which— (A) a summary of the report submitted to the President by the International Trade Commission under section 202(f)(1) of the Trade Act (19 U.S.C. 2252(f)(1)) with respect to the affirmative determination described in paragraph (1)(A) is published in the TA–W No. Subject firm Location 94,800 ............ Ocwen Loan Servicing LLC ........................... 94,826 ............ 94,826A .......... TE Connectivity .............................................. TE Connectivity .............................................. 94,443 ............ 94,485 ............ 94,688 ............ 94,688A .......... 94,688B .......... 93,471 ............ 93,136 ............ 93,136A .......... 93,136B .......... 93,136C ......... TMG Health, A Cognizant Company ............. Ditech Holding Corporation ............................ Fargo Assembly of PA, Inc ............................ Fargo Assembly of PA, Inc ............................ Fargo Assembly of PA, Inc ............................ Payless ShoeSource Worldwide, Inc ............. Sykes Enterprises Incorporated ..................... Sykes Enterprises Incorporated ..................... Sykes Enterprises Incorporated ..................... Sykes Enterprises Incorporated ..................... Fort Washington, PA. Berwyn, PA .... Menlo Park, CA. Jessup, PA .... Rapid City, SD Atchison, KS .. Bethany, MO .. David City, NE Topeka, KS .... Eugene, OR ... Eugene, OR ... Amherst, NY .. Milton Freewater, OR. I hereby certify that the aforementioned determinations were issued during the period of August 1st through August 31st 2019. These determinations are available on the Department’s website https:// www.doleta.gov/tradeact/petitioners/ taa_search_form.cfm under the searchable listing determinations or by calling the Office of Trade Adjustment Assistance toll free at 888–365–6822. VerDate Sep<11>2014 17:37 Sep 23, 2019 Jkt 247001 Federal Register under section 202(f)(3) (19 U.S.C. 2252(f)(3)); OR (B) notice of an affirmative determination described in subparagraph (B) or (C) of paragraph (1) is published in the Federal Register; AND (3) the workers have become totally or partially separated from the workers’ firm within— (A) the 1-year period described in paragraph (2); OR (B) notwithstanding section 223(b) of the Act (19 U.S.C. 2273(b)), the 1-year period preceding the 1-year period described in paragraph (2). Revised Certifications of Eligibility The following revised certifications of eligibility to apply for TAA have been issued. The date following the company name and location of each determination references the impact date for all workers of such determination, and the reason(s) for the determination. The following revisions have been issued. Impact date Reason(s) 3/11/2019 Other. 5/17/2018 5/17/2018 Worker Group Clarification. Worker Group Clarification. 1/3/2018 1/24/2018 4/3/2018 4/3/2018 4/3/2018 1/26/2017 9/12/2016 9/12/2016 9/12/2016 9/12/2016 Worker Worker Worker Worker Worker Worker Worker Worker Worker Worker Group Group Group Group Group Group Group Group Group Group Clarification. Clarification. Clarification. Clarification. Clarification. Clarification. Clarification. Clarification. Clarification. Clarification. Signed at Washington, DC this 10th day of September 2019. Hope D. Kinglock, Certifying Officer, Office of Trade Adjustment Assistance. NUCLEAR REGULATORY COMMISSION [FR Doc. 2019–20601 Filed 9–23–19; 8:45 am] AGENCY: BILLING CODE 4510–FN–P PO 00000 50077 Advisory Committee on the Medical Uses of Isotopes: Meeting Notice Nuclear Regulatory Commission. ACTION: Notice of meeting. The U.S. Nuclear Regulatory Commission (NRC) will convene a teleconference meeting of the Advisory Committee on the Medical Uses of Isotopes (ACMUI) on October 17, 2019, to discuss the draft report of the ACMUI SUMMARY: Frm 00099 Fmt 4703 Sfmt 4703 E:\FR\FM\24SEN1.SGM 24SEN1 50078 Federal Register / Vol. 84, No. 185 / Tuesday, September 24, 2019 / Notices Training and Experience Subcommittee. This report will include the subcommittee’s comments and recommendations on its review of the NRC staff’s evaluation of the training and experience requirements for radiopharmaceuticals under title 10 Code of Federal Regulations (10 CFR) 35.300, ‘‘Use of unsealed byproduct material for which a written directive is required.’’ Meeting information, including a copy of the agenda and handouts, will be available at https:// www.nrc.gov/reading-rm/doccollections/acmui/meetings/2019.html on or about October 2, 2019. The agenda and handouts may also be obtained by contacting Ms. Kellee Jamerson using the information below. DATES: The teleconference meeting will be held on Thursday, October 17, 2019, 2:00 p.m. to 4:00 p.m. Eastern Time. FOR FURTHER INFORMATION CONTACT: Any member of the public who wishes to participate in the teleconference meeting should contact Ms. Jamerson using the contact information below: Kellee Jamerson, email: Kellee.Jamerson@nrc.gov, telephone: (301) 415–7408. SUPPLEMENTARY INFORMATION: Conduct of the Meeting Dr. Darlene Metter, ACMUI Chairman, will preside over the meeting. Dr. Metter will conduct the meeting in a manner that will facilitate the orderly conduct of business. The following procedures apply to public participation in the meeting: 1. Persons who wish to provide a written statement should submit an electronic copy to Ms. Jamerson at the contact information listed above. All submittals must be received by October 11, 2019, three business days prior to the October 17, 2019, meeting and must pertain to the topic on the agenda for the meeting. 2. Questions and comments from members of the public will be permitted during the meeting at the discretion of the Chairman. 3. The draft transcript and meeting summary will be available on ACMUI’s website https://www.nrc.gov/readingrm/doc-collections/acmui/meetings/ 2019.html on or about December 2, 2019. This meeting will be held in accordance with the Atomic Energy Act of 1954, as amended (primarily Section 161a); the Federal Advisory Committee Act (5 U.S.C. App); and the Commission’s regulations in 10 CFR part 7. Dated: September 19, 2019. Russell E. Chazell, Federal Advisory Committee Management Officer. Subject: Federal Register Notice: Advisory Committee on the Medical Uses of Isotopes Meeting Notice. Dated September 19, 2019. ADAMS ML19261C009 OFC MSST/MSEB MSST/MSEB MSST/MSEB NAME ..................................... DATE ..................................... KJamerson ............................. 9/18/2019 ............................... LDimmick * ............................. 9/18/2019 ............................... CEinberg * .............................. 9/18/2019 ............................... SECY RChazell. 9/ /2019. *via email. Official Record Copy [FR Doc. 2019–20612 Filed 9–23–19; 8:45 am] BILLING CODE 7590–01–P NUCLEAR REGULATORY COMMISSION [NRC–2019–0187] Biweekly Notice; Applications and Amendments to Facility Operating Licenses and Combined Licenses Involving No Significant Hazards Considerations Nuclear Regulatory Commission. ACTION: Biweekly notice. AGENCY: Pursuant to the Atomic Energy Act of 1954, as amended (the Act), the U.S. Nuclear Regulatory Commission (NRC) is publishing this regular biweekly notice. The Act requires the Commission to publish notice of any amendments issued, or proposed to be issued, and grants the Commission the authority to issue and make immediately effective any amendment to an operating license or combined license, as applicable, upon a determination by the Commission that such amendment involves no significant khammond on DSKJM1Z7X2PROD with NOTICES SUMMARY: VerDate Sep<11>2014 17:37 Sep 23, 2019 Jkt 247001 hazards consideration, notwithstanding the pendency before the Commission of a request for a hearing from any person. This biweekly notice includes all notices of amendments issued, or proposed to be issued, from August 27, 2019 to September 9, 2019. The last biweekly notice was published on September 10, 2019. DATES: Comments must be filed by October 24, 2019. A request for a hearing must be filed by November 25, 2019. ADDRESSES: You may submit comments by any of the following methods: • Federal Rulemaking Website: Go to https://www.regulations.gov and search for Docket ID NRC–2019–0187. Address questions about NRC dockets IDs in Regulations.gov to Jennifer Borges; telephone: 301–287–9127; email: Jennifer.Borges@nrc.gov. For technical questions, contact the individual listed in the FOR FURTHER INFORMATION CONTACT section of this document. • Mail comments to: Office of Administration, Mail Stop: TWFN–7– A60M, U.S. Nuclear Regulatory Commission, Washington, DC 20555– 0001, ATTN: Program Management, Announcements and Editing Staff. For additional direction on obtaining information and submitting comments, PO 00000 Frm 00100 Fmt 4703 Sfmt 4703 see ‘‘Obtaining Information and Submitting Comments’’ in the SUPPLEMENTARY INFORMATION section of this document. FOR FURTHER INFORMATION CONTACT: Shirley Rohrer, Office of Nuclear Reactor Regulation, U.S. Nuclear Regulatory Commission, Washington, DC 20555–0001; telephone: 301–415– 5411, email: Shirley.Rohrer@nrc.gov. SUPPLEMENTARY INFORMATION: I. Obtaining Information and Submitting Comments A. Obtaining Information Please refer to Docket ID NRC–2019– 0187, facility name, unit number(s), plant docket number, application date, and subject when contacting the NRC about the availability of information for this action. You may obtain publiclyavailable information related to this action by any of the following methods: • Federal Rulemaking Website: Go to https://www.regulations.gov and search for Docket ID NRC–2019–0187. • NRC’s Agencywide Documents Access and Management System (ADAMS): You may obtain publiclyavailable documents online in the ADAMS Public Documents collection at https://www.nrc.gov/reading-rm/ E:\FR\FM\24SEN1.SGM 24SEN1

Agencies

NUCLEAR REGULATORY COMMISSION

[Federal Register Volume 84, Number 185 (Tuesday, September 24, 2019)]
[Notices]
[Pages 50077-50078]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-20612]


=======================================================================
-----------------------------------------------------------------------

NUCLEAR REGULATORY COMMISSION


Advisory Committee on the Medical Uses of Isotopes: Meeting 
Notice

AGENCY: Nuclear Regulatory Commission.

ACTION: Notice of meeting.

-----------------------------------------------------------------------

SUMMARY: The U.S. Nuclear Regulatory Commission (NRC) will convene a 
teleconference meeting of the Advisory Committee on the Medical Uses of 
Isotopes (ACMUI) on October 17, 2019, to discuss the draft report of 
the ACMUI

[[Page 50078]]

Training and Experience Subcommittee. This report will include the 
subcommittee's comments and recommendations on its review of the NRC 
staff's evaluation of the training and experience requirements for 
radiopharmaceuticals under title 10 Code of Federal Regulations (10 
CFR) 35.300, ``Use of unsealed byproduct material for which a written 
directive is required.'' Meeting information, including a copy of the 
agenda and handouts, will be available at https://www.nrc.gov/reading-rm/doc-collections/acmui/meetings/2019.html on or about October 2, 
2019. The agenda and handouts may also be obtained by contacting Ms. 
Kellee Jamerson using the information below.

DATES: The teleconference meeting will be held on Thursday, October 17, 
2019, 2:00 p.m. to 4:00 p.m. Eastern Time.

FOR FURTHER INFORMATION CONTACT: Any member of the public who wishes to 
participate in the teleconference meeting should contact Ms. Jamerson 
using the contact information below: Kellee Jamerson, email: 
[email protected], telephone: (301) 415-7408.

SUPPLEMENTARY INFORMATION: 

Conduct of the Meeting

    Dr. Darlene Metter, ACMUI Chairman, will preside over the meeting. 
Dr. Metter will conduct the meeting in a manner that will facilitate 
the orderly conduct of business. The following procedures apply to 
public participation in the meeting:
    1. Persons who wish to provide a written statement should submit an 
electronic copy to Ms. Jamerson at the contact information listed 
above. All submittals must be received by October 11, 2019, three 
business days prior to the October 17, 2019, meeting and must pertain 
to the topic on the agenda for the meeting.
    2. Questions and comments from members of the public will be 
permitted during the meeting at the discretion of the Chairman.
    3. The draft transcript and meeting summary will be available on 
ACMUI's website https://www.nrc.gov/reading-rm/doc-collections/acmui/meetings/2019.html on or about December 2, 2019.
    This meeting will be held in accordance with the Atomic Energy Act 
of 1954, as amended (primarily Section 161a); the Federal Advisory 
Committee Act (5 U.S.C. App); and the Commission's regulations in 10 
CFR part 7.

    Dated: September 19, 2019.
Russell E. Chazell,
Federal Advisory Committee Management Officer.

    Subject: Federal Register Notice: Advisory Committee on the Medical 
Uses of Isotopes Meeting Notice. Dated September 19, 2019.

                                                ADAMS ML19261C009
----------------------------------------------------------------------------------------------------------------
              OFC                     MSST/MSEB           MSST/MSEB          MSST/MSEB              SECY
----------------------------------------------------------------------------------------------------------------
NAME...........................  KJamerson.........  LDimmick *........  CEinberg *.......  RChazell.
DATE...........................  9/18/2019.........  9/18/2019.........  9/18/2019........  9/ /2019.
----------------------------------------------------------------------------------------------------------------
*via email.

Official Record Copy

[FR Doc. 2019-20612 Filed 9-23-19; 8:45 am]
BILLING CODE 7590-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.